"Genentech is well known for its scientific rigor and commitment in “medical innovations for all”. I am very proud to be a scientist at Genentech and appreciate the opportunities to contribute to multiple development programs that have the potential to improve patient’s lives. It is truly amazing what we learn and discover by “following the science” in our daily work. Translating scientific principles into life-changing medications is my motivation coming to work every day."
Dr. Tang is a principal scientist and therapeutic area lead for autoimmune/inflammation diseases in the department of clinical pharmacology within the development science organization. Soon after joining Genentech in 2009, Dr. Tang was appointed as the pharmacology sub-team leader for two biologic programs and was the clinical pharmacology functional lead managing 8 development programs within inflammation and autoimmune disease areas.
Prior to joining Genentech, Dr. Tang was a Director of PK/PD at PDL Biopharma (previously named as “Protein Design Labs”). Overall, Dr. Tang has near 20 years of Biopharma/Biotech industry experience and was involved in the clinical development of 18 molecules, including monoclonal antibodies, F’ab fragment, Fusion protein and small molecule drugs, primarily in autoimmune or inflammatory disease areas including Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Lupus, Psoriasis and Asthma.
Dr. Tang is responsible for the Clinical Pharmacology (CP) strategy for multiple development projects in order to ensure that appropriate dose/route/schedule decisions are made for the patients. Dr. Tang also supervises multiple CP scientists and scientific researcher(s) to apply state of the art model-informed drug development strategies that are aligned with project strategic context and development needs. Technical expertise include: lead the design & review of CP or clinical study protocols and PK/PD data analysis plans, analysis and interpretation of PK/PD data and exposure-response relationship. Contributed to regulatory discussions regarding clinical pharmacology plan and other development related issues, as well as key regulatory filings/interactions (e.g. IND, End-of Phase 2 meeting, EU Scientific Advice and Type C meetings).